|
Shandong Fengjin Pharmaceutical Co., Ltd., a wholly-owned subsidiary invested by Shandong Fengjin Biopharmaceutical Co., Ltd., is mainly engaged in the research and development, production and sales of chemical APIs, and can undertake a variety of APIs and pharmaceutical intermediates CDMO business. The company was founded in March 2019 with registered capital of RMB 66 million and plans a total investment of RMB 620 million. The project covers a total area of 200,000 square meters and is planned to be completed in three phases. The first phase covers an area of 50,000 square meters and began to construct in February 2020. The main part of the first phase has been completed. The first phase project is expected to be completed in June 2023 and put into operation in July. The company’s current phase API products include febuxostat, rosuvastatin calcium, lenvatinib mesylate, sunitinib malate, sorafenib tosylate, erlotinib hydrochloride, etc.
Shandong Fengjin Pharmaceutical Co., Ltd., a wholly-owned subsidiary invested by Shandong Fengjin Biopharmaceutical Co., Ltd., is mainly engaged in the research and development, production and sales of chemical APIs, and can undertake a variety of APIs and pharmaceutical intermediates CDMO business. The company was founded in March 2019 with registered capital of RMB 66 million and plans a total investment of RMB 620 million. The project covers a total area of 200,000 square meters and is planned to be completed in three phases. The first phase covers an area of 50,000 square meters and began to construct in February 2020. The main part of the first phase has been completed. The first phase project is expected to be completed in June 2023 and put into operation in July. The company’s current phase API products include febuxostat, rosuvastatin calcium, lenvatinib mesylate, sunitinib malate, sorafenib tosylate, erlotinib hydrochloride, etc.
|
|
|
Business Scope: Licensed projects: drug production; drug retail; drug wholesale; drug import and export. (Projects subject to approval by law, the relevant departments for approval before carrying out business activities, specific business projects to the relevant departments for approval of documents or permits shall prevail) General items: import and export of goods; import and export agency; special chemical products manufacturing (excluding hazardous chemicals); basic chemical raw materials manufacturing (excluding hazardous chemicals and other permitted classes of chemicals manufacturing); special chemical products sales (excluding hazardous chemicals); disinfectant sales (excluding hazardous chemicals); the first class of medical equipment sales; technical services, disinfectants sales (excluding hazardous chemicals); technical services, sales of medical equipment; the first class of medical equipment sales. ); disinfectant sales (excluding hazardous chemicals); Class I medical device sales; technical services, technology development, technology consulting, technology exchanges, technology transfer, technology promotion; Internet sales (except for the sale of goods that require licensing); cosmetics retail; cosmetics wholesale. (In addition to projects subject to approval by law, with a business licence to carry out business activities independently according to law) Translated with www.DeepL.com/Translator (free version) Type of Enterprise: limited liability company Location: Thailand India Malaysia Founded Date: 2019-03-07 |
|
|
|
| Country: | China |
|---|---|
| Tel: | |
| Mobile: | 15066764791 |
| E-mail: | liangfulin@fengjin-pharma.com |
| QQ: | 15066764791 |
| Skype: | Chat Now! |
| Address: | No.777 Jinnushan Road, Wuning Street, Muping District, Yantai City, Shandong Province, China |
-
Lenvatinib Mesylate
CAS:857890-39-2 -
Tadalafil
CAS:171596-29-5
$205 -
Erlotinib Hydrochloride
CAS:183319-69-9 -
Policresulen
CAS:9011-02-3 -
Rosuvastatin Calcium
CAS:147098-20-2 -
Telmisartan
CAS:144701-48-4 -
Febuxostat
CAS:144060-53-7 -
Sorafenib Tosylate
CAS:475207-59-1